Duloxetine: a Dual Reuptake Inhibitor

Overview

Journal Ann Pharmacother

Specialty Pharmacology

Date 2004 Nov 4

PMID 15522980

Citations 6

Authors

Sara E Dugan

Matthew A Fuller

Affiliations

Soon will be listed here.

Abstract

Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of duloxetine for the treatment of major depressive disorder (MDD).

Data Sources: Searches using MEDLINE and PsycINFO were conducted (1966 to November 2003).

Study Selection And Data Extraction: All duloxetine MDD information gathered was considered. Articles containing comprehensive information regarding duloxetine use for MDD were evaluated.

Data Synthesis: Duloxetine is a serotonin-norepinephrine reuptake inhibitor being considered for treatment of MDD and stress urinary incontinence. While approved dosing ranges have not yet been determined, studies support the efficacy and safety of 40-60 mg twice daily for the treatment of acute MDD. Adverse effects have been of mild to moderate severity and are considered to be transient. Cardiovascular effects (increased heart rate or blood pressure), while present, do not appear to be clinically significant. Overall, duloxetine appears to be well tolerated.

Conclusions: Duloxetine is a safe and effective antidepressant. Approval of this agent provides another treatment option for the management of MDD.

Citing Articles

Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Kanzawa-Lee G, Knoerl R, Donohoe C, Bridges C, Smith E Semin Oncol Nurs. 2019; 35(3):253-260.

PMID: 31053396 PMC: 6546506. DOI: 10.1016/j.soncn.2019.04.006.

Possible Role of Cyclic AMP Response Element Binding/Brain-Derived Neurotrophic Factor Signaling Pathway in Mediating the Pharmacological Effects of Duloxetine against Methamphetamine Use-Induced Cognitive Impairment and Withdrawal-Induced Anxiety....

Ramezany Yasuj S, Nourhashemi M, Keshavarzi S, Motaghinejad M, Motevalian M Adv Biomed Res. 2019; 8:11.

PMID: 30993081 PMC: 6425746. DOI: 10.4103/abr.abr_34_18.

Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice.

Redaelli M, Ricatti M, Simonetto M, Claus M, Ballabio M, Caretta A PLoS One. 2015; 10(3):e0121883.

PMID: 25812116 PMC: 4374881. DOI: 10.1371/journal.pone.0121883.

Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.

DellOsso B, Camuri G, Dobrea C, Buoli M, Serati M, Altamura A Clin Pract Epidemiol Ment Health. 2012; 8:120-5.

PMID: 23166563 PMC: 3496903. DOI: 10.2174/1745017901208010120.

Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.

Liebowitz M, Tourian K Prim Care Companion J Clin Psychiatry. 2010; 12(3).

PMID: 20944767 PMC: 2947544. DOI: 10.4088/PCC.09r00845blu.